Retina practice marketing: macular degeneration, diabetic eye exams, sudden vision changes and supplement and stem cell claims

A retina practice treats the back of the eye, and its patients arrive with something at stake: a parent who noticed straight lines looking wavy, a person with diabetes sent over after a routine eye exam, someone who saw a shower of new floaters last night, or an adult child researching injections for a mother with macular degeneration. The practice may be a solo retina specialist, a group inside an ophthalmology practice, or a team that also runs clinical trials. This guide covers what the federal patient pages say about age-related macular degeneration (AMD), diabetic eye disease and retinal detachment, the sudden vision change wording that belongs on every page and tool, how to describe treatment without promising sight back, supplement and stem cell claims, diabetic eye exam outreach under HIPAA, prices, referrals, privacy and patient stories.

Eight related topics have their own guides and are not repeated here. Glaucoma screening, eye pressure and drop claims are covered in our guide to glaucoma practice marketing, and general eye care marketing, including the contact lens and eyeglass prescription rules, in our guide to optometry marketing ideas. Cataract surgery and lens upgrades are covered in our guide to premium cataract lens marketing. Selling vitamins in an office is covered in our guide to selling supplements in a medical practice, and cell therapy advertising in our guide to stem cell clinic advertising. Trial recruitment is covered in our guide to clinical trial recruitment ads, Medicare rules in our guide to marketing to Medicare patients, and pages readable by people with low vision in our guide to website accessibility.

What NEI, MedlinePlus, FDA and Medicare say

The National Eye Institute (NEI) publishes the federal patient pages on AMD, diabetic retinopathy and retinal detachment, MedlinePlus from the National Library of Medicine covers macular degeneration and diabetic eye problems, FDA has a consumer page on unapproved regenerative medicine products, and Medicare.gov describes its diabetic eye exam benefit. The NEI AMD and supplement pages were last updated in June 2021, so a practice should quote each page as a dated source and check it again before a campaign. The points that shape a retina practice’s marketing:

• The NEI page Age-Related Macular Degeneration (last updated June 22, 2021) says AMD is a leading cause of vision loss for older adults, that it does not cause complete blindness but loss of central vision makes it harder to see faces, read, drive or do close-up work, and that early AMD has no symptoms, so regular eye exams matter. It says a majority of people with AMD have the dry type, that there is no treatment for early AMD or for late dry AMD (that page predates the 2023 FDA approvals below), that special dietary supplements may stop intermediate AMD from turning into late AMD, and that treatments for wet AMD may be able to stop further vision loss. It says straight lines looking wavy is a warning sign for late AMD and to see an eye doctor right away.
• Drugs@FDA lists two injected drugs approved for geographic atrophy (GA) secondary to AMD: one approved February 17, 2023 and one approved August 4, 2023. The first one’s approved label (February 2023) reports a reduction in the mean rate of GA lesion growth in both studies, and the FDA Drug Trials Snapshot for the second (content current as of October 11, 2024) says the studies showed it slowing the growth of GA lesions. The MedlinePlus encyclopedia page Macular degeneration, age-related (review date July 24, 2025) says that for advanced or severe dry AMD there are no proven treatments that can restore vision.
• The NEI page Treatments for Wet AMD (last updated December 5, 2024) names two options that can slow down or stop vision loss from wet AMD: injections of medicine into the eye and photodynamic therapy. It says the injections generally work for a short time, so a majority of people need them a number of times, at first once a month and then on a schedule the doctor sets.
• The NEI page Nutritional Supplements for Age-Related Macular Degeneration (last updated June 22, 2021) says the AREDS2 formula studied by NEI can help slow vision loss for people with intermediate AMD, cannot prevent early AMD from becoming intermediate AMD, and probably will not help people who already have late AMD in both eyes. It says the supplements can change how other medicines work, that the older formula carries a lung cancer risk for people who smoke or used to smoke, and to talk with a doctor before starting one.
• The NEI page Diabetic Retinopathy (last updated September 11, 2025) says a person with diabetes should get a comprehensive dilated eye exam at least once a year, that early diabetic retinopathy may have no symptoms, and that early treatment can stop the damage and prevent blindness. It says treatment will not undo damage to vision but can stop vision from getting worse, and that some people need a dilated exam every 2 to 4 months.
• The NEI page Retinal Detachment (last updated November 5, 2025) calls retinal detachment a medical emergency and lists its sudden symptoms: a large number of new floaters, flashes of light, and a dark shadow or curtain over part of the field of vision. It says to go to an eye doctor or the emergency room right away.
• The MedlinePlus page Macular Degeneration (last updated October 12, 2024) says treatment can slow vision loss and that it does not restore vision. The MedlinePlus page Diabetic Eye Problems (last updated November 13, 2024) says the treatments for diabetic eye problems are not cures and that eye problems can come back.
• The FDA page Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024) says regenerative medicine therapies have not been approved to treat macular degeneration or blindness, that FDA has received reports of blindness among the harms of unapproved products, and that a person charged for these products outside a clinical trial is likely being deceived and offered a product illegally.
• The Medicare.gov page Eye exams (for diabetes) says Part B covers an eye exam for diabetic retinopathy once a year for people with diabetes, from an eye doctor legally allowed to do the test in the person’s state, and that after the Part B deductible the person pays 20 percent of the Medicare-approved amount, plus a copayment in a hospital outpatient setting.

Two points shape the marketing. First, a sudden change in vision can be a retinal detachment or a stroke, so every page, message and tool must say when to go to the emergency room or call 911 before it offers an appointment. Second, the agency pages say retina treatments can slow or stop vision loss and do not restore what is lost. A practice can explain its care in those terms; it cannot promise sight back.

Sudden vision change wording on every page and in every tool

Put the agency warning signs on the practice pages, above the booking button and the contact form. A short version a practice can use, close to the NEI, MedlinePlus and stroke page words: if you suddenly see a large number of new floaters, flashes of light, or a dark shadow or curtain over part of your vision, go to an eye doctor or the emergency room right away. Seek emergency care for sudden loss of vision in one or both eyes, even if it comes back, sudden double vision, or sudden blurred vision with a red, painful eye. If sudden trouble seeing comes with numbness or weakness of the face, arm or leg, confusion, trouble speaking, or a severe headache, or you think you or someone else is having a stroke, call 911 right away. If straight lines start to look wavy, see your eye doctor right away. Link the NEI and MedlinePlus pages so readers can check them, and have the practice’s retina specialists approve the final wording.

The same wording belongs on voicemail, after-hours messages, patient portal autoreplies, text replies, chat widgets and AI front desk tools. A message that says “a curtain came down over my eye” or “I woke up and cannot see out of one eye” is not a scheduling request. The tool should give the emergency wording and the 911 line at once and alert the on-call doctor’s line, not judge the symptom or offer the next open slot next week. Our guides to AI chatbots on practice websites and answering services and AI receptionists cover how those tools hand off urgent messages.

Phrases that need rewriting:

• “New floaters? Book a retina consult.” NEI calls sudden new floaters with flashes or a curtain a medical emergency. Put the emergency wording first and the booking link after it.
• “Text us a photo of your eye and we will let you know.” Say who reads messages, during which hours, that the inbox is not watched around the clock, and give the emergency wording and 911.
• “Sudden vision loss? It is probably your retina.” MedlinePlus lists stroke among the causes of vision problems. Give the 911 line for sudden trouble seeing with other stroke signs.

Macular degeneration: injections, dry AMD and “restore vision” claims

On AMD pages, the line to hold is what the agency pages support. NEI says there is no treatment for early AMD, that wet AMD treatments may be able to stop further vision loss, and that injections generally need repeating. MedlinePlus says treatment does not restore vision. For GA secondary to AMD, FDA approved two injected drugs in 2023, and the FDA sources describe slower lesion growth, not restored sight. The NEI AMD page (last updated June 22, 2021) predates those approvals, so a page should not quote its line that late dry AMD has no treatment. A page can describe what the practice offers in those words: how the practice watches early and intermediate AMD with regular exams, what an injection visit involves, that treatment is ongoing and the doctor sets the schedule, and what support exists for people living with low vision. Name no medicine. A page that wants to state that a specific product is FDA approved for a use links the FDA source and has counsel review the wording.

A page about dry AMD should be plain about what each option does: NEI lists no treatment for early AMD, the two injected drugs FDA approved in 2023 for GA are described by FDA as slowing lesion growth, MedlinePlus says no proven treatment restores vision in advanced dry AMD, and research, including NEI-supported stem cell studies, is testing whether new treatments are safe. Where the practice runs or refers to a trial, our trial recruitment guide covers how to describe it without implying the treatment works.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. “See your grandchildren clearly again” implies restored vision even without the word.

Phrases that need rewriting:

• “Restore your vision with our AMD treatment.” MedlinePlus says treatment does not restore vision. Say treatment for wet AMD may slow or stop further vision loss.
• “Stop macular degeneration.” NEI lists no treatment for early AMD, and FDA describes the two injected drugs approved in 2023 for GA as slowing lesion growth, not stopping it. Say what the practice does for each type and stage.
• “One injection and you are done.” NEI says the injections generally work for a short time and need repeating. Say the doctor sets the schedule.
• “Never go blind from AMD.” An outcome promise. Quote the NEI wording on what AMD does and what treatment can do.
• “Our results are better than other retina practices.” A comparative claim. Remove it unless the practice has the evidence, the measure, the period and counsel’s review.

Supplements and stem cell claims

An AMD page that covers supplements can quote NEI: the AREDS2 formula studied by NEI can help slow vision loss for people with intermediate AMD or late AMD in one eye, it cannot prevent early AMD from progressing, it probably will not help late AMD in both eyes, and a patient talks with the doctor before starting it because it can change how other medicines work. Leave out ingredient amounts and product names, and do not sell or link a brand from a clinical page. A practice that sells supplements in the office follows our supplement guide, and any claim that a supplement treats or prevents an eye disease falls under 15 U.S.C. 45 and 52 and the FTC guidance above. The FDA page Questions and Answers on Dietary Supplements explains why a supplement sold with a claim to treat a disease is treated as a drug.

Stem cell and other regenerative offers for the eye carry the highest risk. The FDA page says regenerative medicine therapies have not been approved to treat macular degeneration or blindness, that FDA has received reports of blindness from unapproved products, and that charging for these products outside a clinical trial is likely illegal. It also says listing on clinicaltrials.gov or registering with FDA does not mean a product is legally marketed. A retina practice should not advertise cell, exosome or cord blood treatments for eye disease outside an FDA-overseen trial, and should not borrow trial language to sell care. Our stem cell advertising guide covers the wider rules.

Phrases that need rewriting:

• “Stem cell therapy to reverse macular degeneration.” FDA says these therapies have not been approved to treat macular degeneration. Remove it.
• “FDA registered stem cell clinic.” FDA says registration does not mean a product is legally marketed. Remove it.
• “The eye vitamin that stops AMD.” NEI says the formula can help slow vision loss at certain stages and cannot prevent early AMD from progressing. Quote NEI and name no brand.
• “Everyone over 50 should take eye vitamins.” NEI ties the supplements to intermediate or one-eye late AMD and says to talk with a doctor first. Remove it.

Diabetic eye exam outreach and HIPAA

Diabetic eye disease is the part of retina marketing that reaches people before they notice a problem. NEI says a person with diabetes should get a dilated eye exam at least once a year and that early treatment can stop damage, and Medicare.gov describes a yearly covered exam for people with diabetes. Outreach built on those facts helps patients. How the practice reaches them is where the privacy rules apply.

Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder that a patient’s yearly diabetic eye exam is due, a recall after an injection, or a care coordination message to the patient, can fall outside the definition of marketing. A message paid for by a drug or device maker, or one that promotes a third party’s product such as a supplement, generally needs a signed authorization under 45 CFR 164.508, and goes to counsel before it is sent. The same applies in the other direction: a primary care or endocrine practice that hands its list of patients with diabetes to the retina practice so the retina practice can advertise to them is a marketing use that 164.508 generally requires an authorization for. A referral of a named patient for care is different from a list for a campaign, and counsel reviews any list-sharing plan first.

Keep the diagnosis, test results and stage of disease out of text and email message text. “Your yearly eye exam is due, call [phone]” says enough. Our guides to text message appointment reminders and patient recall systems cover the wording and the setup, and our guides to diabetes education programs and endocrinology practices cover the other side of the referral.

Phrases that need rewriting:

• “Your diabetic retinopathy check is overdue.” Names a condition in message text. Say the yearly eye exam is due.
• “Free diabetic eye screening for all patients of Dr. [Clinician name, license].” A list-based offer to another practice’s patients. Counsel reviews any list sharing first.
• “Diabetes? Your eyes are fine if you can see well.” NEI says early diabetic retinopathy may have no symptoms. Quote NEI on yearly dilated exams.

Prices, free screenings and the Medicare share

A practice that posts a self-pay price for an exam or a scan follows the rules in our guide to advertising cash prices, and gives uninsured and self-pay patients the estimate described in our guide to good faith estimates.

A retina practice adds a few points of its own:

• Say what each price includes and what it does not: the exam, dilation, imaging, the injection visit, the medicine itself and follow-up visits.
• Do not write “covered by Medicare” without the rest. Medicare.gov describes one covered diabetic eye exam a year, with the Part B deductible and 20 percent of the Medicare-approved amount after it. Say the patient’s share depends on their coverage.
• Injection treatment is ongoing. A price page that shows one visit says the doctor sets the number of visits that follow.
• “Free” screenings follow 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere.
• A free screening is still an exam with a result someone must act on. Say who reviews it, how the person is told and where they go if treatment is needed.

Referrals, co-management and drug makers

A retina practice draws patients from optometrists, general ophthalmologists, primary care and endocrine practices, and it deals with makers of injected medicines and imaging devices. Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Where the practice or its partners bill Medicare or Medicaid, the statute reaches each of these relationships. Rules on referral fees are also set state by state. Our guide to patient and physician referrals covers the general rules.

For a retina practice, keep these points:

• Do not give gifts, meals, free services or payments to referring optometrists or physicians in return for patients without counsel’s review.
• Co-management arrangements with referring eye doctors, where follow-up care is shared, go to counsel first.
• Funding, meals, speaker fees or free staff from medicine or device makers go to counsel first. Payments to physicians may be reported publicly; our guide to Open Payments covers that.
• Patients are not paid or given gifts for choosing the practice or for referring friends.
• Practices that see Medicaid patients follow the rules in our guide to marketing to Medicaid patients.

Privacy, pixels, ads and readable pages

A visit to an AMD injection page, a diabetic exam booking or an uploaded scan says something about a person’s health. Keep bookings, intake answers, images and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with AMD or diabetes.

Retina patients and their readers include people with low vision. A page that zooms cleanly, has strong contrast, works with a screen reader and offers a phone number next to every form serves them; our website accessibility guide covers the standards.

Patient stories

A patient who describes how injection visits fit into their week, or how a low vision referral helped them keep cooking, can help a reader facing the same diagnosis. It is still one person’s experience. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. “I can read again” is a results claim. Keep stories to the experience of care, and pair them with the agency wording that treatment can slow vision loss and does not restore it.

Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, and consent for any photo, video or retinal image. Name no medicine or supplement, say if the patient received anything for taking part, and let the patient review the final version. Our guide to testimonials and before and after photos covers the full rules, including scan comparisons.

Illustration: two retina practice pages

Illustration: a page reads “Restore your vision. Our advanced injections stop macular degeneration, and our stem cell program can reverse dry AMD. Take our eye vitamin to protect your sight. New floaters? Book a consult.” It promises restored sight that MedlinePlus says treatment does not give, claims to stop a disease where NEI lists no treatment for early AMD and FDA describes the GA drugs as slowing lesion growth, offers a therapy FDA says is not approved for macular degeneration, sells a supplement with a disease claim and puts a booking link where the emergency wording belongs.

Illustration: a second page for the same practice reads “If you suddenly see a large number of new floaters, flashes of light or a curtain over your vision, go to an eye doctor or the emergency room right away. If sudden trouble seeing comes with weakness, confusion or trouble speaking, call 911. At [Practice name], [Clinician name, license] treats macular degeneration and diabetic eye disease. Treatment for wet AMD may slow or stop further vision loss; it does not restore vision lost already, and injections are repeated on a schedule your doctor sets. If you have diabetes, the National Eye Institute advises a dilated eye exam at least once a year. Visits at [days and hours]. Call [phone].” It puts the emergency wording first, describes treatment in the agency words and promises nothing it cannot show.

Checklist before a retina campaign goes live

• NEI, MedlinePlus, FDA and Medicare.gov pages named and dated, with a “last reviewed” date and reviewer on each clinical page.
• Sudden vision change wording, the emergency room line and the 911 line for stroke signs above any booking button, and in voicemail, portal replies, text replies, chat and AI front desk tools.
• Treatment described as slowing or stopping further vision loss; no “restore vision”, “stop AMD” or “never go blind” lines.
• No medicine, supplement or device names, no ingredient amounts, no supplement sold with a disease claim.
• No stem cell, exosome or cord blood offers for eye disease outside an FDA-overseen trial; no “FDA registered” claims.
• Diabetic exam reminders about the practice’s own care only; no diagnosis or results in message text; no marketing to another practice’s patient list without counsel’s review and authorization.
• Prices say what is included, that injection care is ongoing and that the Medicare share depends on coverage; free offers follow 16 CFR 251.1.
• No gifts or payments to referral sources; co-management and maker arrangements reviewed by counsel.
• Bookings, scans and results stay out of pixels and ad audiences; targeting by place and search terms only.
• Pages tested for zoom, contrast and screen readers, with a phone number next to every form.
• Stories have signed authorizations, name no medicine or supplement, make no results claim and carry a statement of what people can generally expect.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including eye care practices. For a retina practice, that means a site that quotes NEI and MedlinePlus as written, puts the sudden vision change wording above the booking button, explains injections, supplements and diabetic eye exams in plain words and reads well for people with low vision, plus booking and contact forms that keep diagnoses and scans off the web and away from tracking tools. Our front desk tools hand urgent messages to the emergency wording and the 911 line, and do not triage symptoms. We do not decide who needs treatment; your retina specialists do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• National Eye Institute: Age-Related Macular Degeneration (last updated June 22, 2021)
• National Eye Institute: Treatments for Wet AMD (last updated December 5, 2024)
• National Eye Institute: Nutritional Supplements for Age-Related Macular Degeneration (last updated June 22, 2021)
• National Eye Institute: Diabetic Retinopathy (last updated September 11, 2025)
• National Eye Institute: Retinal Detachment (last updated November 5, 2025)
• MedlinePlus: Macular Degeneration (last updated October 12, 2024)
• MedlinePlus: Diabetic Eye Problems (last updated November 13, 2024)
• MedlinePlus Medical Encyclopedia: Vision problems (review date August 5, 2024)
• MedlinePlus: Stroke (last updated July 28, 2025)
• FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• Drugs@FDA: NDA 217171, GA drug approved February 17, 2023
• FDA: label for NDA 217171 (approved February 2023)
• Drugs@FDA: NDA 217225, GA drug approved August 4, 2023
• FDA: Drug Trials Snapshot for NDA 217225 (content current as of October 11, 2024)
• MedlinePlus Medical Encyclopedia: Macular degeneration, age-related (review date July 24, 2025)
• Medicare.gov: Eye exams (for diabetes) (checked October 30, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing